Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

* ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development * The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia * NAVER D2S...

2026-09-18 23:00 3659

Datasea's AI Agent Digital Marketing Services Enter Scaled Commercial Deployment, with Five Agreements Representing Potential Annualized Service Volume of Up to Approximately US$89.4 Million (RMB600 Million)

Five-customer AI agent services advance into actual delivery; CEO reiterates long-term confidence through a previously disclosed US$1.0 million Rule 10b5-1 share purchase plan BEIJING, Sept. 17, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"),...

2026-09-17 21:10 4788

Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR

— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...

2026-09-17 19:00 2602

111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dat...

2026-09-17 16:25 5984

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...

2026-09-17 16:09 2841

111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...

2026-09-17 15:00 6915

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...

2026-09-17 14:34 2070

Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site

* Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to re...

2026-09-16 22:28 3833

Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site

Datasea Expands into China's Trillion-RMB Silver Economy Through Strategic Cooperation in AI Elderly Care Robots

Datasea plans to combine its AI agent and digital platform capabilities with its partner's robotics technologies and elderly care deployment experience to develop intelligent care solutions for China's rapidly growing silver economy BEIJING, Sept. 16, 2026 /PRNewswire/ -- Datasea Intelligent Tech...

2026-09-16 21:28 4880

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one ...

2026-09-16 16:57 2660

Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

* Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field * Presentation expected to provide the first clinical evidence that a small activating RNA (saRNA) can u...

2026-09-15 22:19 3409

Totaria Highlights Magnesium Nutrition Awareness During Healthy Aging Month

AURORA, Colo., Sept. 15, 2026 /PRNewswire/ -- As September marks Healthy Aging Month in the United States, premium American nutritional supplement brand Totaria is raising awaren...

2026-09-15 21:12 2107

Totaria Highlights Magnesium Nutrition Awareness During Healthy Aging Month

Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder

BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist being de...

2026-09-15 18:00 1968

RIGHT CARE, RIGHT PLACE: NUHS MARKS A DECADE OF ADVANCING VALUE-BASED CARE, SAVING 18,225 BED DAYS

The NUHS Appropriate and Value-Based Care Symposium 2026 showcases a decade of proven impact — providing value-based care to over 300,000 patients, saving 18,225 bed days, and advancing a model for healthcare transformation across Singapore SINGAPORE, Sept. 15, 2026 /PRNewswire/ -- More than 300...

2026-09-15 17:04 1977

RIGHT CARE, RIGHT PLACE: NUHS MARKS A DECADE OF ADVANCING VALUE-BASED CARE, SAVING 18,225 BED DAYS

Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026

HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...

2026-09-15 14:14 2472

Yuyu Pharma Expands Solar Power at Manufacturing Facility, Bringing On-Site Capacity to 1 MW

New solar installation expected to supply more than 30% of the factory's electricity needs and pay for itself in approximately three years SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) has completed a major expansion of solar power at its manufacturing facility in ...

2026-09-14 21:00 3558

NEXTBIOMEDICAL Marks Its Largest-Ever Presence at CIRSE 2026 with Exhibition Booth and Learning Center, Highlighting Global Clinical Evidence

SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- NEXTBIOMEDICAL, a medical device company specializing in innovative therapeutic solutions, participated in CIRSE 2026, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held in Copenhagen, Denmark, from ...

2026-09-14 21:00 4286

Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA

* Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. * LP-003 is the first innovative drug independently developed by LongBio Pharma to advance to BLA s...

2026-09-14 21:00 3411

NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

An innovative approach for breast cancer treatment uses localised and non-invasive pulsed electromagnetic fields to reprogram immune cells, turning them from tumour helpers to cancer killers SINGAPORE, Sept. 14, 2026 /PRNewswire/ -- Researchers from the National University of Singapore (NUS) hav...

2026-09-14 14:14 4515

Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical ...

2026-09-14 14:00 2227

1 2 3 456 7 8 ... 263